RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- Change in substantial holding
- RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
- Notice of Extraordinary General Meeting and Proxy Form
- Share Purchase Plan - Now Open
Later from Radiopharm Theranostics
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- Ceasing to be a substantial holder
- RAD Doses First Patient in Second Cohort of BetaBart (RV-01)
- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
- Change of Director's Interest Notices x 4
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics